GSA Capital Partners LLP Buys New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Key Points

• GSA Capital Partners LLP has acquired a new position in Dyne Therapeutics, purchasing 98,597 shares valued at approximately $1,031,000, representing about 0.09% of the company's stock.
• CEO John Cox bought 100,000 shares at an average price of $9.11, increasing his stake in the company by 70.33% to 242,179 shares valued at over $2.2 million.
• Dyne Therapeutics reported a quarterly earnings per share of ($0.97), beating analyst expectations, with a consensus target price of $36.25 reflecting a "Moderate Buy" rating among research analysts.

GSA Capital Partners LLP acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 98,597 shares of the company's stock, valued at approximately $1,031,000. GSA Capital Partners LLP owned approximately 0.09% of Dyne Therapeutics as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of DYN. GF Fund Management CO. LTD. acquired a new stake in Dyne Therapeutics in the 4th quarter valued at $50,000. Arizona State Retirement System grew its position in Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after purchasing an additional 1,481 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Dyne Therapeutics by 22.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company's stock valued at $201,000 after purchasing an additional 3,496 shares during the period. Summit Investment Advisors Inc. boosted its holdings in Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after acquiring an additional 721 shares during the last quarter. Finally, Neo Ivy Capital Management purchased a new position in Dyne Therapeutics during the 4th quarter worth $205,000. Institutional investors own 96.68% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Raymond James Financial reaffirmed an "outperform" rating and set a $31.00 price objective (down from $37.00) on shares of Dyne Therapeutics in a report on Tuesday, July 29th. Robert W. Baird cut their price objective on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a report on Wednesday, June 18th. Sanford C. Bernstein assumed coverage on shares of Dyne Therapeutics in a report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price objective on the stock. Guggenheim reiterated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Finally, Stifel Nicolaus lowered their target price on Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $36.25.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock traded up $0.38 during midday trading on Tuesday, reaching $10.63. The stock had a trading volume of 1,729,882 shares, compared to its average volume of 2,562,844. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $47.45. The firm's 50-day moving average price is $10.68 and its 200 day moving average price is $11.40. The firm has a market capitalization of $1.51 billion, a PE ratio of -2.76 and a beta of 1.08. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.02. As a group, research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox acquired 100,000 shares of the business's stock in a transaction dated Monday, July 14th. The stock was bought at an average price of $9.11 per share, with a total value of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares of the company's stock, valued at $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 14.14% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.